Kamada, Baxter sales and marketing update

Kamada granted Baxter exclusive rights to commercialize Glassia in the U.S., Australia, New Zealand and Canada. Kamada will receive $20 million up front and is eligible for up to $25 million in milestones, plus royalties. FDA approved the intravenous formulation of alpha 1-antitrypsin ( AAT) to treat AAT deficiency last month. Baxter, which plans to launch Glassia in the U.S. next quarter, will look to out-license commercialization rights in the other countries where it has rights (see BioCentury, July 12). ...